期刊文献+

对一个CDR区发生突变的改形抗CD28重链单域抗体的研究 被引量:4

The Study of a Reshaping Anti-CD28 Heavy-chain Variable Domain(V_H) Antibody with CDR Mutations
下载PDF
导出
摘要 在构建改形抗CD2 8重链单域抗体时 ,得到一个具有较高免疫学活性的改形抗CD2 8重链单域抗体基因序列。其推导氨基酸序列与改形构建时所选的人源抗体的FRs同源性最高 ;其推导氨基酸序列与鼠源抗CD2 8单克隆抗体重链可变区氨基酸序列比较发现 ,该改形抗体在CDR2区 53位缺失Ala氨基酸残基 ;而在 65a位上插入一个Arg氨基酸残基。在CDR3区缺少Asp95,Lys96,Gly97,Tyr98氨基酸残基。在FR3区缺少Lys82a ,Ser82b ,Leu82c氨基酸残基。由于该序列发生的突变较大 ,作者进一步对其进行了研究。该改形抗CD2 8VH 单域抗体基因与人c myc及人IgG3’CL绞链区基因在大肠杆菌中融合表达。融合表达包涵体经复性 ,纯化处理后 ,仍具有较高与人CD2 8分子结合活性。 One gene with CDR mutations of the reshaping anti CD28 heavy chain variable domain(V H) antibodies, which had high antigen binding activity, was obtained from a phage library of the reshaping anti CD28 heavy chain variable domain(V H) antibodies. It's deduced amino acid sequence was most homologous as the acceptor human antibody FRs. To compare it's deduced amino acid sequence with the original mouse anti human CD28 V H amino acid sequence, We found that there were a deletion mutation of Ala 53 and a insertion mutation of Arg 65a in CDR2; deletion mutations of Asp 95 ,Lys 96 ,Gly 97 ,Tyr 98 in CDR3; and deletion mutations of Lys 82a ,Ser 82b ,Leu 82c in FR3. Because there were many mutations in this gene, a further study was carried out. It was co expressed with c myc tag and the hinge region of human IgG3'CL gene in E.coli. BL21, and the results of ELISA showed that antigen binding activity of the refolding fusion protein was still kept in a high level.
出处 《高技术通讯》 EI CAS CSCD 2001年第4期11-15,共5页 Chinese High Technology Letters
基金 863计划资助项目! ( 863 10 2 0 9 0 4 0 1)
关键词 CD28 改形抗体 单域抗体 突变体 免疫学活性 基因工程 基因疗法 T细胞 CD28, Reshaping antibody, Mutations, Antigen binding activity
  • 相关文献

参考文献2

  • 1Moore J C,J Mol Biol,1997年,272卷,336页
  • 2Kabat E A,NIH Bethesda,1991年,91页

同被引文献19

  • 1沈关心 周汝麟 沈关心 周汝麟主编.外周血单个核细胞的分离与纯化[A].沈关心,周汝麟主编.现代免疫学技术 第2版[C].湖北:湖北科学技术出版社,2002.377-379.
  • 2Jefferis R, Lund J, Goodall M. Modulation of FcγR and Human Complement Activation by IgG3-eore Oligosaccharlde Interactions[J]. Immunol Lett, 1996,54(2-3) :101-104.
  • 3Pini A, Viti F, Santucei A, et al. Design and Use of Ohage Dispiay Library[J]. J Biol Chem, 1998, 273 (34) : 21 769-21 776.
  • 4Hoogenboom HR, De Bruine AP, Hufton SE, et al. Antibody Phage Display Technology and Its Applications[J]. Immunotechnology, 1998,4(1) : 1-20.
  • 5Kabat E A,Wu T T,Perry H M,et al. Sequences of Proteins of Immunogical Interest[M]. 6th ed. Bethesda MD: US Department of Health and Human Service. National Institutes of Health, 1996.
  • 6L. Z. Yu, S. Xiao, H. H. Huang, et al. Construction and Expression of Single Chain Fv Antibody Against Bladder Carcinoma[J], Urological Research, 1996,24 : 273-277.
  • 7[美]J.萨姆布鲁克,E.F.弗里奇,T.曼尼阿蒂斯.分子克隆实验指南[M].金冬雁,黎孟枫译.第2版,北京:科学出版社,1999.
  • 8Borrebaeck C A K. Antibody Engineering[M], 2nd ed. New York: Oxford University Press, 1995.
  • 9MacDonald RA, Hosking C S, Jones C L. The Measurement of Relative Affinity by ELISA Using Thiocyanate Elution[J]. J Immunol Methods, 1988,106 : 191-194.
  • 10Merluzzi S, Figini M, Colombatti A, et al. Humanized Antibodies as Potential Drugs for Therapeutic Use[J]. Adv. Clin Path,2000,4(2) :77-85.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部